Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
Key facts
- Who runs it
- Zenas BioPharma (USA), LLC
- Where
- Atlanta, Boston, Detroit, Naples, and Stanford, United StatesSee the 5 sitesAlso in 17 other countries, 71 sites
- Trial code
- NCT05662241
- EU 2022-500718-24-00
- U1111-1281-5874
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 194 people enrolled
- Started
- 9 Jan 2023
- Expected to end
- 15 Feb 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Obexelimab
- Placebo
- Record updated
- 4 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Males and females, ≥ 18 years of age
- Clinical diagnosis of IgG4-RD
- Patients must meet the 2019 ACR/EULAR Classification Criteria for IgG4-RD
- Patients must have active IgG4-RD signs/symptoms (i.e., flare) that require the initiation of GC therapy or the increase in background long-term GC therapy
- Other inclusion criteria apply
Who cannot take part
- Has received prednisone equivalent given orally at a dose greater than 60 mg/day within the 4 weeks prior to screening or during screening
- Has received a non-biologic, disease-modifying anti-rheumatological drug or immunosuppressive agent other than GCs within the 2 weeks prior to screening
- Has received an investigational treatment or direct medical intervention on another clinical study within 12 weeks or < 5 half-lives of the investigational treatment, whichever is shorter, prior to screening
- Has received live vaccine or live therapeutic infectious agent within the 2 weeks prior to screening
- Has disease in only 1 organ system whose primary manifestation is fibrosis
- Active tuberculosis or high risk for tuberculosis; hepatitis C infection in absence of curative treatment; evidence of hepatitis B infection
- Use of B cell depleting or targeting agents within 6 months of randomization
- Other exclusion criteria apply
Where in United States
Also in 17 other countries, 71 sites
- Emory UniveristyAtlanta, United States
- Massachusetts General HospitalBoston, United States
- Henry Ford HospitalDetroit, United States
- GI PROS Research - Dedicated Research FacilityNaples, United States
- Stanford MedicineStanford, United States
About the trial
What the trial wants to find out
This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)
The 2 groups in the trial
- ZB012Treatment being tested
Obexelimab administered as an SC injection.
Treatment: Obexelimab
- PlaceboPlacebo, for comparison
Placebo administered as an SC injection.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO)
- Publications
- Obexelimab for the Treatment of IgG4-Related Disease.The New England journal of medicine, 2026
- Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.Rheumatology and therapy, 2026
- Record updated
- 4 February 2026